More importantly, IDH1 mutations also regulate anti-tumor immunity via decreasing PD-L1 expression and reducing immunosuppressive cell infiltration, indicating its potential possibility in GBM immunotherapy (49). The gene discussed is IDH1; the disease is neoplasm.